SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Sites
2.2. Ethics
2.3. Laboratory Assay
2.4. Job Title, COVID-19 Symptoms, and Diagnosis
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Nawa, N.; Kuramochi, J.; Sonoda, S.; Yamaoka, Y.; Nukui, Y.; Miyazaki, Y.; Fujiwara, T. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): A household- and population-based study. medRxiv 2020. [Google Scholar] [CrossRef]
- Ministry of Health, Labour and Welfare. A Report of Antib. Prevalence Surveillance in Japan (Japanese). Available online: https://www.mhlw.go.jp/content/000734482.pdf (accessed on 15 March 2021).
- Galanis, P.; Vraka, I.; Fragkou, D.; Bilali, A.; Kaitelidou, D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: A systematic review and meta-analysis. J. Hosp. Infect. 2021, 108, 120–134. [Google Scholar] [CrossRef] [PubMed]
- Hibino, M.; Iwabuchi, S.; Munakata, H. SARS-CoV-2 IgG seroprevalence among medical staff in a general hospital that treated patients with COVID-19 in Japan: Retrospective evaluation of nosocomial infection control. J. Hosp. Infect. 2021, 107, 103–104. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, A.; Yamamoto, S.; Miyo, K.; Mizoue, T.; Maeda, K.; Sugiura, W.; Mitsuya, H.; Sugiyama, H.; Ohmagari, N. Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan. J. Infect. 2021. [Google Scholar] [CrossRef] [PubMed]
- Fujita, K.; Kada, S.; Kanai, O.; Hata, H.; Odagaki, T.; Satoh-Asahara, N.; Tagami, T.; Yasoda, A. Quantitative SARS-CoV-2 Antibody Screening of Healthcare Workers in the Southern Part of Kyoto City During the COVID-19 Pre-pandemic Period. Front. Public Health 2020, 8, 595348. [Google Scholar] [CrossRef] [PubMed]
- Rostami, A.; Sepidarkish, M.; Leeflang, M.M.G.; Riahi, S.M.; Nourollahpour Shiadeh, M.; Esfandyari, S.; Mokdad, A.H.; Hotez, P.J.; Gasser, R.B. SARS-CoV-2 seroprevalence worldwide: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2020, 3, 331–340. [Google Scholar] [CrossRef] [PubMed]
- Abo-Leyah, H.; Gallant, S.; Cassidy, D.; Giam, Y.H.; Killick, J.; Marshall, B.; Hay, G.; Pembridge, T.; Strachan, R.; Gallant, N.; et al. Seroprevalence of SARS-COV-2 Antibodies in Scottish Healthcare Workers. medRxiv 2020. [Google Scholar] [CrossRef]
- Flehmig, B.; Schindler, M.; Ruetalo, N.; Businger, R.; Bayer, M.; Haage, A.; Kirchner, T.; Klingel, K.; Normann, A.; Pridzun, L.; et al. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients. Viruses 2020, 12, 1357. [Google Scholar] [CrossRef] [PubMed]
- Gudbjartsson, D.F.; Norddahl, G.L.; Melsted, P.; Gunnarsdottir, K.; Holm, H.; Eythorsson, E.; Arnthorsson, A.O.; Helgason, D.; Bjarnadottir, K.; Ingvarsson, R.F.; et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 2020, 383, 1724–1734. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Li, J.; Li, H.; Lei, P.; Shen, G.; Yang, C. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. Int. Immunopharmacol. 2021, 90, 107271. [Google Scholar] [CrossRef] [PubMed]
- Choe, P.G.; Kim, K.-H.; Kang, C.K.; Suh, H.J.; Kang, E.; Lee, S.Y.; Kim, N.J.; Yi, J.; Park, W.B.; Oh, M. Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. Emerg. Infect. Dis. 2021, 27, 928–931. [Google Scholar] [CrossRef]
August 2020 | October 2020 | |||||||
---|---|---|---|---|---|---|---|---|
Region (Prefecture) | n | Positive, n (%) | n | Positive, n (%) | ||||
IgM | IgG | IgM and/or IgG | IgM | IgG | IgM and/or IgG | |||
Fukuoka | 1746 | 10 (0.6) | 25 (1.4) | 33 (1.9) | 1698 | 3 (0.2) | 24 (1.4) | 27 (1.6) |
Kumamoto | 321 | 0 (0) | 0 (0) | 0 (0) | 308 | 0 (0) | 0 (0) | 0 (0) |
Tokyo | 75 | 0 (0) | 0 (0) | 0 (0) | 75 | 0 (0) | 0 (0) | 0 (0) |
Total | 2142 | 10 (0.5) | 25 (1.2) | 33 (1.5) | 2081 | 3 (0.1) | 24 (1.2) | 27 (1.3) |
Nosocomial infection (−) | 1654 | 10 (0.6) | 13 (0.8) | 21 (1.3) | 1595 | 3 (0.2) | 13 (0.8) | 16 (1.0) |
Nosocomial infection (+) | 488 | 0 (0) | 12 (2.5) | 12 (2.5) | 486 | 0 (0) | 11 (2.3) | 11 (2.3) |
p-value a,b | 0.09 | 0.003 | 0.06 | 0.34 | 0.009 | 0.03 |
Characteristics | n | IgM Positive n (%) | IgG Positive n (%) | IgM and/or IgG Positive, n (%) |
---|---|---|---|---|
Total | 2160 | 10 (0.5) | 28 (1.3) | 36 (1.7) |
COVID-19 history (−) | 2146 | 10 (0.5) | 18 (0.8) | 26 (1.2) |
COVID-19 history (+) | 14 | 0 (0) | 10 (71.4) | 10 (71.4) |
Age | ||||
20–29 | 411 | 2 (0.5) | 11 (2.7) | 12 (2.9) |
30–39 | 587 | 3 (0.5) | 1 (0.2) | 3 (0.5) |
40–49 | 601 | 3 (0.5) | 7 (1.2) | 10 (1.7) |
50–59 | 330 | 0 (0.0) | 4 (1.2) | 4 (1.2) |
60–69 | 174 | 2 (1.2) | 5 (2.9) | 7 (4.0) |
≥70 | 57 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
p value d | 0.60 | 0.006 | 0.007 | |
Sex | ||||
Female | 1547 | 6 (0.4) | 21 (1.4) | 27 (1.8) |
Male | 613 | 4 (0.7) | 7 (1.1) | 9 (1.5) |
p value d | 0.41 | 0.69 | 0.65 | |
Job categories | ||||
Nurse a | 651 | 3 (0.5) | 11 (1.7) | 14 (2.2) |
Physician | 97 | 0 (0.0) | 1 (1.0) | 1 (1.0) |
Technician b | 369 | 2 (0.5) | 3 (0.8) | 4 (1.1) |
Nursing care staff | 329 | 2 (0.6) | 8 (2.4) | 9 (2.7) |
Office worker | 270 | 2 (0.7) | 2 (0.7) | 4 (1.5) |
Receptionist | 33 | 0 (0.0) | 1 (3.0) | 1 (3.0) |
Clinical research unit worker | 192 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Other c | 219 | 1 (0.5) | 2 (0.9) | 3 (1.4) |
p value d | 0.95 | 0.25 | 0.33 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yoshihara, T.; Ito, K.; Zaitsu, M.; Chung, E.; Aoyagi, I.; Kaji, Y.; Tsuru, T.; Yonemura, T.; Yamaguchi, K.; Nakayama, S.; et al. SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan. Int. J. Environ. Res. Public Health 2021, 18, 3786. https://doi.org/10.3390/ijerph18073786
Yoshihara T, Ito K, Zaitsu M, Chung E, Aoyagi I, Kaji Y, Tsuru T, Yonemura T, Yamaguchi K, Nakayama S, et al. SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan. International Journal of Environmental Research and Public Health. 2021; 18(7):3786. https://doi.org/10.3390/ijerph18073786
Chicago/Turabian StyleYoshihara, Tatsuya, Kazuya Ito, Masayoshi Zaitsu, Eunhee Chung, Izumi Aoyagi, Yoshikazu Kaji, Tomomi Tsuru, Takuma Yonemura, Koji Yamaguchi, Shinichi Nakayama, and et al. 2021. "SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan" International Journal of Environmental Research and Public Health 18, no. 7: 3786. https://doi.org/10.3390/ijerph18073786